Cyclobenzaprine hydrochloride
Suppliers
Names
[ CAS No. ]:
6202-23-9
[ Name ]:
Cyclobenzaprine hydrochloride
[Synonym ]:
Cyclobenzaprine hydrochloride
3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine Hydrochloride
MK 130 HCl
3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine hydrochloride (1:1)
3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine hydrochloride
3-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine,hydrochloride
3-(5H-Dibenzo[a,d][7]annulen-5-yliden)-N,N-dimethylpropan-1-aminhydrochlorid
1-propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride
MFCD00079039
1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride (1:1)
3-(5H-Dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride (1:1)
3-(5H-dibenzo[a,d][7]annulén-5-ylidène)-N,N-diméthylpropan-1-amine chlorhydrate
10,11d-Amitriptyline Hydrochloride
N,N-Dimethyl-5H-dibenzo[a,d]cycloheptene-D5,g-propylamine Hydrochloride
EINECS 228-264-4
Cyclobenzaprine (hydrochloride)
Chemical & Physical Properties
[ Boiling Point ]:
405.9ºC at 760 mmHg
[ Melting Point ]:
216-218ºC
[ Molecular Formula ]:
C20H22ClN
[ Molecular Weight ]:
311.848
[ Flash Point ]:
9℃
[ Exact Mass ]:
311.144073
[ PSA ]:
3.24000
[ LogP ]:
5.35580
[ Storage condition ]:
-20°C Freezer
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- HP0875000
- CHEMICAL NAME :
- 5H-Dibenzo(a,d)cycloheptene-delta(sup 5)-gamma-propylamine, N,N-dimethyl-, hydrochloride
- CAS REGISTRY NUMBER :
- 6202-23-9
- LAST UPDATED :
- 199504
- DATA ITEMS CITED :
- 7
- MOLECULAR FORMULA :
- C20-H21-N.Cl-H
- MOLECULAR WEIGHT :
- 311.88
- WISWESSER LINE NOTATION :
- L C676 BHJ B3N1&1 &GH
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 5714 ug/kg/2D-I
- TOXIC EFFECTS :
- Behavioral - wakefulness Behavioral - euphoria Behavioral - hallucinations, distorted perceptions
- REFERENCE :
- JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 54,39,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 1 mg/kg/3D-I
- TOXIC EFFECTS :
- Behavioral - wakefulness Behavioral - euphoria Behavioral - hallucinations, distorted perceptions
- REFERENCE :
- JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 54,39,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 12 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - hallucinations, distorted perceptions Cardiac - pulse rate increase, without fall in BP
- REFERENCE :
- JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 20,281,1983
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 8400 ug/kg/2W-I
- TOXIC EFFECTS :
- Behavioral - general anesthetic
- REFERENCE :
- JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,151,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 250 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,87,1972
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 36 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 144,481,1963 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5339 No. of Facilities: 100 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 656 (estimated) No. of Female Employees: 512 (estimated)
Safety Information
[ Symbol ]:
GHS02, GHS06, GHS08
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H225-H301 + H311 + H331-H370
[ Precautionary Statements ]:
P210-P260-P280-P301 + P310-P311
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves
[ Hazard Codes ]:
Xn: Harmful;
[ Risk Phrases ]:
R20/21/22
[ Safety Phrases ]:
36
[ RIDADR ]:
UN 2811 6.1/PG 3
[ WGK Germany ]:
3
[ RTECS ]:
HP0875000
[ Packaging Group ]:
III
[ Hazard Class ]:
6.1(b)
[ HS Code ]:
2942000000
Customs
[ HS Code ]: 2921499090
[ Summary ]:
2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%
Articles
Forensic Sci. Int. 243 , 35-43, (2014)
The aim of this study was to develop an LC-MS/MS based screening technique that covers a broad range of acidic and neutral drugs and poisons by combining a small sample volume and efficient extraction...
Reprod. Toxicol. 37 , 1-5, (2013)
To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception.Women enrolled in the Enviro...
J. Oral Facial Pain Headache 28(2) , 119-27, (2014)
To compare the effectiveness of adding cyclobenzaprine, tizanidine, or placebo to patient education and a self-care management program for patients with myofascial pain and specifically presenting wit...